Adenocarcinoma clinical trials at UCLA
1 research study open to eligible people
Showing trials for
JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
open to eligible males ages 18 years and up
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of JNJ-69086420 in Part 1 (Dose Escalation) and to determine safety and preliminary signs of clinical activity at the RP2D(s) in Part 2 (Dose Expansion).
Duarte, California and other locations
Our lead scientists for Adenocarcinoma research studies include Jeremie Calais.
Last updated: